

          -  Known allergy to (components of) the BCG vaccine or serious adverse events to prior
             BCG administration

          -  Known active or latent Mycobacterium tuberculosis or with another mycobacterial
             species. A history with- or a suspicion of M. tuberculosis infection.

          -  Fever (>38 C) within the past 24 hours

          -  Pregnancy

          -  Suspicion of active viral or bacterial infection

          -  Vaccination in the past 4 weeks or expected vaccination during the study period,
             independent of the type of vaccination.

          -  Severely immunocompromised subjects. This exclusion category comprises: a) subjects
             with known infection by the human immunodeficiency virus (HIV-1); b) neutropenic
             subjects with less than 500 neutrophils/mm3; c) subjects with solid organ
             transplantation; d) subjects with bone marrow transplantation; e) subjects under
             chemotherapy; f) subjects with primary immunodeficiency; g) severe lymphopenia with
             less than 400 lymphocytes/mm3; h) treatment with any anti-cytokine therapies. i)
             treatment with oral or intravenous steroids defined as daily doses of 10mg prednisone
             or equivalent for longer than 3 months, or probable use of oral or intravenous
             steroids in the following four weeks

          -  Active solid or non-solid malignancy or lymphoma within the prior two years

          -  Direct involvement in the design or the execution of the BCG-CORONA study

          -  Expected absence from work of >=4 of the following 12 weeks due to any reason
             (holidays, maternity leave, retirement, planned surgery etc)

          -  Employed to the hospital < 22 hours per week

          -  Not in possession of a smartphone
      